CoChat

Effects of 1-Year Treatment With Highly Purified Omega-3 Fatty Acids on Depression After Myocardial Infarction: Results From the OMEGA Trial

The DOI matches its Crossref record.

Abstract

OBJECTIVE: The effects of supplementation of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on prevalence and severity of depression were evaluated in patients after a myocardial infarction. METHOD: A cross-sectional evaluation (posttest-only design) within the prospective, randomized, controlled, multicenter OMEGA trial was performed in patients after myocardial infarction at 12 months' follow-up (N = 2,081; age, mean = 64 years; men, 76.7%; women, 21.8%) from April 2005 to June 2007. Patients received supplementation with ethyl esters 90 (460-mg EPA and 380-mg DHA) or placebo for 12 months. Depression was assessed with the Beck Depression Inventory-II (BDI-II); a BDI-II cutoff score of ≥ 14 was used as diagnosis of depression. RESULTS: When the total population was evaluated, no effects of EPA/DHA supplementation on depressive symptoms according to BDI-II score (mean [SD]) could be demonstrated: EPA/DHA (n = 1,046), 7.1 (6.9); placebo (n = 1,035), 7.1 (7.0); P = .7. The post hoc analyses of depressed patients with and without antidepressants revealed a tendency toward an antidepressant effect in patients with EPA/DHA supplementation as monotherapy: EPA/DHA (n = 125), 19.4 (5.8); placebo (n = 113), 19.9 (5.1); P = .07. However, in depressed patients with EPA/DHA supplementation as adjunctive to conventional antidepressants, a clinically relevant antidepressant effect was demonstrated: EPA/DHA (n = 33), 20.9 (7.1); placebo (n = 29), 24.9 (8.5); P < .05. CONCLUSIONS: EPA/DHA supplementation in the total sample of patients after myocardial infarction had no effect on depressive symptoms. The clinically relevant antidepressant effect in the subgroup of depressed patients with EPA/DHA supplementation as adjunctive to conventional antidepressants that was revealed in the post hoc analysis might provide a basis for a controlled, prospective trial of omega-3 augmentation of antidepressants in patients after myocardial infarction. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00251134.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.13m08453

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 25

Metadata

Authors
Zimmer, R., Riemer, T., Rauch, B., Schneider, S., Schiele, R., Gohlke, H., Diller, F., Steinbeck, G., Katus, H., Senges, J., & OMEGA-Study Group
Affiliations
TUM Klinikum (DE)
Corresponding author
Zimmer, Reinhilde
Venue
The Journal of Clinical Psychiatry
Published
2013-11-15
Volume
74
Issue
11
Pages
e1037-e1045
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2085106486
Cited by
25
References
0
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 5 · 2014: 1
FWCI
2.46
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, depression, myocardial infarction, antidepressant augmentation, fatty acid supplementation, ethyl esters, depressive symptoms, antidepressant monotherapy, adjunctive therapy, Beck Depression Inventory-II
MeSH terms
Aged, Cross-Sectional Studies, Depressive Disorder, Fatty Acids, Unsaturated, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Personality Inventory, Prospective Studies, Psychometrics, Eicosapentaenoic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of 1-Year Treatment With Highly Purified Omega-3 Fatty Acids on Depression After Myocardial Infarction: Results From the OMEGA Trial. https://app.cochat.ai/papers/10.4088/jcp.13m08453
The paper
Zimmer, R., Riemer, T., Rauch, B., Schneider, S., Schiele, R., Gohlke, H., Diller, F., Steinbeck, G., Katus, H., Senges, J., & OMEGA-Study Group. (2013). Effects of 1-Year Treatment With Highly Purified Omega-3 Fatty Acids on Depression After Myocardial Infarction: Results From the OMEGA Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13m08453

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.